Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1

Clinical Cancer Research

Volumn 11, Issue 18, 2005, Pages 6730-6737

  Mohanty, Sanghamitra ^a   Huang, Jie ^a   Basu, Alakananda ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BRYOSTATIN 1; CISPLATIN; LIPOCORTIN 5; PHORBOL DIBUTYRATE; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C DELTA; SMALL INTERFERING RNA;

ARTICLE; CANCER RESISTANCE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME REGULATION; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; HELA CELLS; HUMANS; INDOLES; LACTAMS; MACROLIDES; PHORBOL 12,13-DIBUTYRATE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-DELTA; RNA INTERFERENCE; RNA, SMALL INTERFERING; TETRADECANOYLPHORBOL ACETATE; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 25144434873     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0450     Document Type: Article

References (35)

1. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cell 1990;2:275-9.
2. Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1991;18:11-24.
3. Hofmann J, Doppler W, Jakob A, et al. Enhancement of the antiproliferative activity of cis-diamminedichloroplainum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 1988;42:382-8.
4. Isonishi S, Andrews PA, Howell SB. Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem 1990;265:3623-7.
5. Basu A, Teicher BA, Lazo JS. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem 1990;265:8451-7.
6. Basu A, Lazo JS. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res 1992;52:3119-24.
7. Basu A, Kozikowski AP, Saw K, Lazo JS. Cellular sensitization to cis-diamminedichloroplatinum (II) by novel analogs of protein kinase C activator lyngbyatoxin A. Cancer Res 1991;51:2511-4.
8. Basu A, Woolard MD, Johnson CL. Involvement of protein kinase C-δ in DNA damage-induced apoptosis. Cell Death Differ 2001;8:899-908.
9. Basu A, Akkaraju GR. Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C. Biochemistry 1999;38:4245-51.
10. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607-13.
11. Parker PJ, Parkinson SJ. AGC protein kinase phosphorylation and protein kinase C. Biochem Soc Trans 2001;29:860-3.
12. Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 2003;370:361-71.
13. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 1993;59:257-80.
14. Stabel S, Parker PJ. Protein kinase C. Pharmacol Ther 1991;51:71-95.
15. Basu A. Involvement of PKC-δ in DNA damage-induced apoptosis. J Cell Mol Med 2003;7:341-50.
16. Brodie C, Blumberg PM. Regulation of cell apoptosis by protein kinase c δ. Apoptosis 2003;8:19-27.
17. Ghayur T, Hugunin M, Talanian RV, et al. Proteolytic activation of protein kinase C δ by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 1996;184:2399-404.
18. Mizuno K, Noda K, Araki T, et al. The proteolytic cleavage of protein kinase C isotypes, which generates kinase and regulatory fragments, correlates with Fas-mediated and 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis. Eur J Biochem 1997;250:7-18.
19. Matassa AA, Carpenter L, Biden TJ, Humphries MJ, Reyland ME. PKCδ is required for mitochondrial-dependent apoptosis in salivary epithelial cells. J Biol Chem 2001;276:29719-28.
20. Leverrier S, Vallentin A, Joubert D. Positive feedback of protein kinase C proteolytic activation during apoptosis. Biochem J 2002;368:905-13.
21. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCδ promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003;63:780-6.
22. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. Isolation and structure of bryostatin 1. J Am Chem Soc 1982;104:6846-8.
23. Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promoters: Sixth Rhoads Memorial Award Lecture. Cancer Res 1988;48:1-8.
24. Gschwendt M, Fürstenberger G, Rose-John S, et al. Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol esters TPA in vivo and in vitro. Carcinogenesis 1988;9:555-62.
25. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores R, Yuspa SH. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 1987;8:555-62.
26. Schuchter LM, Esa AH, May WS, Laulis MK, Pettit GR, Hess AD. Successful treatment of murine melanoma with bryostatin 1. Cancer Res 1991;51:682-7.
27. Huang J, Mohanty S, Basu A. Cisplatin resistance is associated with deregulation in protein kinase C-δ. Biochem Biophys Res Commun 2004;316:1002-8.
28. Vindelov LL, Christensen IbJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
29. Basu A, Evans RW. Comparison of effects of growth factors and protein kinase C activators on cellular sensitivity to cis-diamminedichloroplatinum(II). Int J Cancer 1994;58:587-91.
30. Johnson CL, Lu D, Huang J, Basu A. Regulation of p53 stabilization by DNA damage and protein kinase C. Mol Cancer Ther 2002;1:861-7.
31. Gschwendt M. Protein kinase Cδ. Eur J Biochem 1999;259:555-64.
32. Haas NB, Smith M, Lewis N, et al. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study Clin Cancer Res 2003;9:109-14.
33. Dowlati A, Lazarus H, Hartman P, et al. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Clin Cancer Res 2003;9:5929-35.
34. Kortmansky J, Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest 2003;21:924-36.
35. Nezhat F, Wadler S, Muggia F, et al. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 2004;93:144-8.